The RPSC has announced the RAS mains result 2025, with 2,461 candidates declared successful. The mains exam was held on June 17 and 18, 2025, across multiple centres in Rajasthan in two shifts daily.

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

Marking a historic milestone, the U.S. Coast Guard announced Monday the combined interdiction of more than 76,140 pounds of illicit narcotics. The quantity of drugs offloaded at Port Everglades is the ...

ISLAMABAD: Long association of Dr Mukhtar Ahmed with the Higher Education Commission (HEC) has come to an end as Prime Minister Shehbaz Sharif appointed the federal secretary education as the acting ...

The federal government has appointed Secretary Education Nadeem Mahbub as the acting chairman of Higher Education Commission since Dr Mukhtar Ahmed’s term has ended. The Ministry of Education has ...

The Higher Education Commission (HEC) of Pakistan has launched a major digital transformation initiative to improve public universities across the country. This project aims to replace old, ...

If you’re buying a new TV, you’ll need to decide whether to use a TV stand or mount it on the wall. There are a number of good reasons why wall-mounting a TV can make sense. First, it can make the set ...

While the system has the "ingredients" necessary for top-tier university rankings, poor governance remains a significant barrier to progress, Chairman of the Higher Education Commission (HEC) Dr ...

A local court in Islamabad ordered the reinstatement of Dr Ziaul Qayyum as Executive Director of the Higher Education Commission (HEC). However, despite the court's orders, the HEC administration did ...

ISLAMABAD – The court has reinstated Professor Dr. Zia-ul-Qayyum as the Executive Director of the Higher Education Commission (HEC) after suspending his termination orders issued earlier this year.

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.